Axon's Cash Flow Cut Exposes the Cost of Its Skydio Ambitions

Axon Enterprise is asking investors to fund a bigger vision at the very moment it is delivering less cash than promised. The company's stock fell 18% on Friday after quarterly results and a trimmed full-year outlook triggered heavy selling, with the guidance details first disclosed in a mandatory filing on Thursday. The sell-off frames a sharper question than any single quarter: can Axon keep buying growth while its own forecasts slip?

A $1.2 Billion Bet Lands Alongside a Warning

On Thursday Axon announced it will deploy $1.2 billion into Skydio, split between cash and its own shares. The package covers fresh capital for the drone maker as well as the purchase of stock from existing shareholders. Beyond the equity stake, Axon is set to become Skydio's exclusive distribution partner for public safety across the United States and Canada.

The strategic appeal lies in that channel position — access to the business rather than a passive holding — provided the arrangement pays off commercially. Both transactions are expected to close in the fourth quarter of 2026 and the first quarter of 2027, subject to customary conditions. Until then, the financial and operational impact stays a matter of execution.

What gives the announcement its edge is the timing. Axon cut its free cash flow target from $450 million to a range of $350 million to $400 million. Less money coming in, and more capital going out, is a combination that raises the bar for everything management does next.

Delayed Federal Projects Explain the Trim

Three Dedrone projects at the federal level, worth roughly $130 million in revenue, have slipped, according to the company. That figure alone shows why a handful of schedule changes can move a full-year outlook. Axon cited these delays as the reason for lowering its revenue growth guidance.

Should investors sell immediately? Or is it worth buying Axon?

The cash flow forecast now becomes the clearest yardstick for coming reports. Hitting the new range against a steadier operating backdrop would point to a more predictable trajectory. If that target also comes under pressure, the skeptical case gains ground. Delayed projects and margin trends give investors concrete markers for either outcome.

Growth Still Cuts the Other Way

The bull case rests on scale that has not slowed. Axon reported third-quarter 2026 revenue of $908.6 million, up 28% year over year. That expansion offsets some of the disappointment, though it only carries weight if paired with firmer cash generation. Converting the delayed projects and easing margin pressure would let shareholders read the guidance cut as a matter of timing rather than deterioration.

For the fourth quarter of 2026, Axon guided revenue to between $990 million and $1.01 billion. Those results will serve as the first real test of the revised plan.

Two Analysts, Two Verdicts

Friday's research notes captured the split. Piper Sandler's James Fish trimmed his price target to $540 from $561 while keeping an Overweight rating, pointing to delayed Dedrone orders and softer Taser trends. The target cut shows that even the optimistic camp is now pricing in lower expectations.

Craig-Hallum's Jeremy Hamblin moved the other way, downgrading Axon from Buy to Hold with a $390 target, citing the weak quarter, a soft outlook for the closing quarter and the delayed federal Dedrone contracts. Raymond James, meanwhile, maintained its Outperform rating and lowered its target to $475.

The spread of reactions — from caution to continued conviction at reduced targets — mirrors the tension in the story itself.

Axon at a turning point? This analysis reveals what investors need to know now.

Margins Are the Second Front

Fish also flagged product gross margins below 50%. That puts earnings quality in the spotlight alongside project timing. Should the pressure persist, later revenue recognition would only partly ease concerns about the financial surplus Axon generates.

The bear case is not one problem but several running at once. If projects keep slipping and margins stay thin, confidence in the new plan erodes, and Friday's decline becomes the start of a longer re-rating rather than a single bad day.

What Has to Go Right

The Skydio agreement can strengthen Axon's distribution position if the closing goes through and real business follows. Financial credibility, in turn, depends on converting delayed projects and meeting the adjusted targets. The next phase will be judged on how well those two strands hold together — expansion on one side, delivery on the other.

Ad

Axon Stock: New Analysis - 9 November

Fresh Axon information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Axon analysis...